Free Trial
Biren Amin

Biren Amin Analyst Performance

Sr. Research Analyst at Piper Sandler

Biren Amin is a stock analyst at Piper Sandler in the medical sector, covering 38 publicly traded companies. Over the past year, Biren Amin has issued 28 stock ratings, including buy and hold recommendations. While full access to Biren Amin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Biren Amin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
100 Last 11 Years
Buy Recommendations
80.00% 80 Buy Ratings
Companies Covered
38 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy80.0%80 ratings
Hold19.0%19 ratings
Sell1.0%1 ratings

Out of 100 total stock ratings issued by Biren Amin at Piper Sandler, the majority (80.0%) have been Buy recommendations, followed by 19.0% Hold and 1.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
97.4% of companies on NASDAQ
37 companies
NYSEAMERICAN
2.6% of companies on NYSEAMERICAN
1 company

Biren Amin, an analyst at Piper Sandler, currently covers 38 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
38 companies
100.0%

Biren Amin of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
25 companies
65.8%
MED - DRUGS
6 companies
15.8%
PHARMACEUTICAL PREPARATIONS
3 companies
7.9%
SURGICAL & MEDICAL INSTRUMENTS
1 company
2.6%
MED - GENERIC DRG
1 company
2.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
2.6%
BIOTECHNOLOGY
1 company
2.6%

About Biren Amin

Biren Amin is a managing director and senior research analyst on the healthcare equity research team covering biotechnology companies. Prior to joining Piper Sandler, Amin served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors. Before Pyramid Biosciences, Amin served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases. Prior to Jefferies Financial Group Inc., Amin spent seven years in various equity research roles covering the biotechnology sector. Amin graduated from University of the Sciences with a bachelor's degree in pharmacy. He received his master's degree from Long Island University and his Master of Business Administration degree from the Leonard Stern School of New York University.
Follow on LinkedIn

Biren Amin's Ratings History at Piper Sandler

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/13/2026Reiterated Rating$7.72$18.00Overweight
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
5/12/2026Downgrade$9.99$12.00Neutral
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
5/5/2026Boost Price Target$4.53$11.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
3/31/2026Initiated Coverage$749.29$875.00Overweight
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3/24/2026Boost Price Target$3.02$7.00Overweight
Immatics N.V. stock logo
IMTX
Immatics
3/16/2026Initiated Coverage$9.71$18.00Buy
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3/13/2026Boost Price Target$2.39$8.00Overweight
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2/26/2026Boost Price Target$89.09$140.00Overweight
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2/20/2026Initiated Coverage$1.76$7.00Overweight
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2/20/2026Initiated Coverage$1.70$7.00Overweight
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2/19/2026Initiated Coverage$5.03$16.00Overweight
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2/19/2026Initiated Coverage$5.65$16.00Overweight
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
11/25/2025Initiated Coverage$2.00$7.00Overweight
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
11/5/2025Initiated Coverage$33.25$48.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
10/30/2025Boost Price Target$23.20$16.00Neutral
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
10/30/2025Boost Price Target$65.44$98.00Overweight
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
10/10/2025Boost Price Target$46.25$67.00Overweight
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
10/3/2025Boost Price Target$11.06$31.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/25/2025Set Price Target$72.87$95.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/29/2025Boost Price Target$13.86$15.00Neutral
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
7/23/2025Set Price Target$2.57$3.00Neutral
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/21/2025Lower Price Target$13.79$18.00Neutral
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/14/2025Boost Price Target$46.47$68.00Overweight
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
7/10/2025Initiated Coverage$1.62$6.00Overweight
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
6/26/2025Reiterated Rating$0.64$4.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/16/2025Downgrade$36.18$36.00Neutral
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/16/2025Lower Price Target$2.84$17.00Overweight
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
5/14/2025Lower Price Target$0.93$7.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
5/7/2025Lower Price Target$38.37$70.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4/30/2025Boost Price Target$38.50$63.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4/21/2025Lower Price Target$53.62$110.00Overweight
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
4/14/2025Initiated Coverage$21.95$51.00Overweight
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3/31/2025Initiated Coverage$14.59$38.00Overweight
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
3/21/2025Downgrade$0.28$0.70Neutral
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2/19/2025Initiated Coverage$3.17$12.00Overweight
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
1/30/2025Downgrade$13.19$4.00Neutral